leaders in innovation
UNIPHYLLIN Continus 200mg, 300mg and 400mg Prolonged-Release Tablets are indicated in the treatment and prophylaxis of bronchospasm and inflammation associated with asthma, chronic bronchitis and emphysema. Also indicated in adults for the treatment of cardiac asthma and left ventricular or congestive cardiac failure.
UNIPHYLLIN Continus 200mg, 300mg and 400mg Prolonged-Release Tablets are indicated in the treatment and prophylaxis of bronchospasm and inflammation associated with asthma, chronic bronchitis and emphysema. Also indicated in adults for the treatment of cardiac asthma and left ventricular or congestive cardiac failure.
PHYLLOCONTIN CONTINUS 225 mg Prolonged Release Tablets are indicated for the treatment and prophylaxis of bronchospasm and inflammation associated with asthma, emphysema and chronic bronchitis. Also indicated in adults for the treatment of cardiac asthma and left ventricular or congestive cardiac failure.
PHYLLOCONTIN CONTINUS 225 mg Prolonged Release Tablets are indicated for the treatment and prophylaxis of bronchospasm and inflammation associated with asthma, emphysema and chronic bronchitis. Also indicated in adults for the treatment of cardiac asthma and left ventricular or congestive cardiac failure.
flutiform 50mcg/5mcg, 125mcg/5mcg and 250mcg/10mcg fixed-dose combinations of fluticasone propionate and formoterol fumarate (Flutiform inhaler)are indicated in the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting beta2 agonist) is appropriate: • For patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting 2 agonist. Or • For patients already adequately controlled on both an inhaled corticosteroid and a long-acting 2 agonist. Flutiform inhalers are indicated in adults and adolescents aged 12 years and above.
flutiform 50mcg/5mcg, 125mcg/5mcg and 250mcg/10mcg fixed-dose combinations of fluticasone propionate and formoterol fumarate (Flutiform inhaler)are indicated in the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting beta2 agonist) is appropriate: • For patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting 2 agonist. Or • For patients already adequately controlled on both an inhaled corticosteroid and a long-acting 2 agonist. Flutiform inhalers are indicated in adults and adolescents aged 12 years and above.
LEADERS IN INNOVATION

Mundipharma Pharmaceuticals associated companies, Mundipharma Research Limited in Cambridge and Mundipharma Research GmbH in Germany, are young,...

PATIENT SUPPORT

What is asthma?
Asthma is a common medical condition that affects the lungs.
More specifically, asthma causes...

PRODUCTS FOR PEOPLE

We are actively involved in the following therapeutic areas: Analgesia, Oncology, and Respiratory.

 

Analgesia is our...

GLOBAL NETWORK

Mundipharma Pharmaceuticals Limited is an Irish company and is part of a network of independent associated companies across Europe. This...

keep me informed

Keep me Informed

Receive Emails about special offers, promotions, products and news.

Mundipharma newsletter

events calendar
Events Calendar
Medical Information &

Medical Information & Adverse Events

Contact Medical Information on:

01 2063800
1800 991 830 (outside office hours)

For Adverse Events email: